FYERS
Home
/
Stocks
/
Results
/
RPG Life Sciences Results

RPG Life Sciences Results

Financial overview

CAGR%
Sales
Profits
Returns
ROE
10Y5Y3YTTM
---8%
----37%
18%29%19%4%
27%27%27%20%

Peer Comparison

Symbol
SUNPHARMA
DIVISLAB
TORNTPHARM
LAURUSLABS
ZYDUSLIFE
DRREDDY
CIPLA
MANKIND
AUROPHARMA
LUPIN
RPGLIFE
PriceM.Cap (₹)PE RatioEPS (₹)EV/EBITDAAnnual PAT
1,784.4₹425150 Cr38.778.2958.23₹11479 Cr
10,003₹266265 Cr91.0334.04128.41₹2568 Cr
4,692.3₹176301 Cr8314.04106.21₹2163 Cr
2,308.3₹125352 Cr93.568.1733.94₹889 Cr
1,206₹123591 Cr27.399.4262.53₹5040 Cr
1,367₹114351 Cr40.8411.0859.2₹4196 Cr
1,395.4₹112474 Cr38.8210.8652.6₹3879 Cr
2,513.9₹102315 Cr45.6217.2376.26₹1913 Cr
1,707.6₹97757 Cr26.3317.9596.84₹3505 Cr
2,021.7₹92007 Cr16.6430.95154.35₹5333 Cr
2,599.4₹4195 Cr38.3516.0880.54₹115 Cr

Profit & Loss

Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
₹212 Cr₹196 Cr₹177 Cr₹180 Cr₹182 Cr₹169 Cr₹143 Cr₹173 Cr
₹4 Cr₹5 Cr₹12 Cr₹3 Cr₹5 Cr₹5 Cr₹5 Cr₹3 Cr
₹216 Cr₹200 Cr₹189 Cr₹183 Cr₹186 Cr₹174 Cr₹148 Cr₹176 Cr
₹178 Cr₹158 Cr₹150 Cr₹146 Cr₹148 Cr₹139 Cr₹123 Cr₹129 Cr
₹45 Cr₹48 Cr₹45 Cr₹43 Cr₹44 Cr₹41 Cr₹31 Cr₹52 Cr
₹84 L₹63 L₹39 L₹25 L₹12 L₹13 L₹18 L₹12 L
₹37 Cr₹41 Cr₹40 Cr₹29 Cr₹49 Cr₹35 Cr₹135 Cr₹47 Cr
₹28 Cr₹31 Cr₹30 Cr₹22 Cr₹37 Cr₹26 Cr₹117 Cr₹35 Cr

Balance Sheet

Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Secured Loans
Deferred Tax Assets / Liabilities
Other Long Term Liabilities
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Provisions
Total Current Liabilities
Total Liabilities
Contingent Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Capital Work in Progress
Non Current Investments
Long Term Investment
Long Term Loans & Advances
Total Non-Current Assets
Current Assets Loans & Advances
Currents Investments
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
Mar 2026Mar 2025
——
₹13 Cr₹13 Cr
₹592 Cr₹517 Cr
₹592 Cr₹517 Cr
₹605 Cr₹531 Cr
₹13 Cr₹0
₹3 Cr-₹1 Cr
₹3 Cr₹3 Cr
₹7 Cr₹5 Cr
₹27 Cr₹6 Cr
——
₹97 Cr₹79 Cr
₹33 Cr₹24 Cr
₹30 Cr₹16 Cr
₹161 Cr₹120 Cr
₹793 Cr₹657 Cr
₹18 Cr₹14 Cr
₹20 Cr₹0
——
₹321 Cr₹276 Cr
₹125 Cr₹104 Cr
₹197 Cr₹172 Cr
₹20 Cr₹4 Cr
₹1 Cr₹1 Cr
₹1 Cr₹1 Cr
₹13 Cr₹3 Cr
₹234 Cr₹192 Cr
——
₹84 Cr₹126 Cr
₹124 Cr₹93 Cr
₹117 Cr₹87 Cr
₹192 Cr₹140 Cr
₹16 Cr₹10 Cr
₹28 Cr₹10 Cr
₹559 Cr₹465 Cr
₹399 Cr₹345 Cr
₹793 Cr₹657 Cr
₹366₹321
₹366₹321

Cash Flow

Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Closing Cash & Cash Equivalent
Mar 2026Mar 2025
₹154 Cr₹233 Cr
-₹17 Cr-₹76 Cr
-₹43 Cr-₹26 Cr
₹94 Cr₹131 Cr
₹57 Cr₹78 Cr
₹86 Cr-₹42 Cr
-₹21 Cr-₹27 Cr
₹122 Cr₹9 Cr
₹29 Cr₹20 Cr
₹150 Cr₹29 Cr

Fundamental Ratios

Consolidated
Standalone
Empty box

No results found

Share Price Live Stats

Open (₹)2,542.00
Volume (₹)7,083.00
High (₹)2,609.00
Upper Circuit3,035.50
Low (₹)2,522.50
Lower Circuit2,023.70
Prev Close2,529.60
52W High (₹)3,127.80
Price2,599.40
52W Low (₹)1,733.00

Share Market Cap & Key Ratios Overview

M.Cap (₹)4194.79 Cr
Div. Yield (%)0.95
PE Ratio38.35
Debt to Equity0.03
Price to Book5.05
Book Value366.05
EPS (TTM)66.14
Face Value8.00
ROE (%)20.28

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats
1. Premium insight available after login
2. Sign in to view full SWOT analysis
3. Unlock strengths, weaknesses, opportunities & threats
Sign in to view
Open a free Demat account in minutes to start investing and screening .
LoginSign Up

QVT

Quality
0/100-
Valuation
0/100-
Technical
0/100-
Sign in to view
Open a free Demat account in minutes to start investing and screening .
LoginSign Up

Peer Stocks

1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
LAURUSLABSNSE
ZYDUSLIFENSE
DRREDDYNSE
CIPLANSE
MANKINDNSE
AUROPHARMANSE
LUPINNSE
RPGLIFENSE
LTP
1W Low
1W High
Market cap (₹)
1784.4+6.7 (0.38%)
1722
1810.40
4,25,150Cr
10003+223 (2.28%)
9863
10067
2,66,265Cr
4692.3+78.9 (1.71%)
4553
4703.10
1,76,301Cr
2308.3-97.2 (-4.04%)
2252.40
2441.90
1,25,352Cr
1206-39.5 (-3.17%)
1182.40
1266.60
1,23,591Cr
1367+15 (1.11%)
1336.70
1376.70
1,14,351Cr
1395.4+16.5 (1.20%)
1364.60
1400.80
1,12,474Cr
2513.9+21.1 (0.85%)
2457.90
2515
1,02,315Cr
1707.6+26.2 (1.56%)
1656.20
1724.60
97,757Cr
2021.7+10.7 (0.53%)
1988.90
2062.10
92,007Cr
2599.4+23.7 (0.92%)
2480
2609
4,195Cr

RPG Life Sciences Ltd Annual Results Key Takeaways

Operating profit (before other income, interest and exceptional items) was ₹47.99Cr; with other income of ₹4.7Cr, profit before interest and tax came to ₹42.09Cr. Interest expense was ₹63Lakh; PBT before exceptional items stood at ₹41.46Cr. Cost mix (full year): raw materials ₹255.21Cr; employee cost ₹141.48Cr; depreciation ₹5.9Cr; other expenses ₹152.4Cr. Basis: consolidated annual results.

RPG Life Sciences Ltd Quaterly Results Key Takeaways

RPG Life Sciences Ltd reported ₹195.69Cr total income from operations in Jun 2026, softer than ₹176.89Cr in Mar 2026 but higher than ₹143.09Cr in Mar 2025. Operating profit (before other income, interest and exceptional items) was ₹47.99Cr; with other income of ₹4.7Cr, profit before interest and tax came to ₹42.09Cr. Interest expense was ₹63Lakh, taking profit before tax to ₹41.46Cr. After tax of ₹10.7Cr, profit after tax stood at ₹30.76Cr (vs ₹29.9Cr in Mar 2026 and ₹117.35Cr in Mar 2025).